CA SB1452

Prohibits health care service plans and health insurers from determining which manufacturer's biological products or biosimilars are used when medically necessary products are prescribed, effective for contracts issued, amended, or renewed on or after January 1, 2021.

Bans health care service plans and health insurers from requiring prior authorization or step therapy to limit which manufacturer's biological products or biosimilars are administered by a physician or clinician.

Applies to biological products and biosimilars covered as medical benefits, including physician- or clinician-administered products in hospitals, clinics, infusion centers, offices, or other health care facility settings.

Defines "biological products" and "biosimilars" according to Section 262(i) of Title 42 of the United States Code.

Specifies that no state reimbursement is required because costs incurred by local agencies relate to crime-related changes governed by Section 17556 of the Government Code.